Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05701488 · ClinicalTrials.gov registry record · Phase 1
SIRT With Tremelimumab and Durvalumab for Resectable HCC
A Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer, sponsored by Jiping Wang, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT05701488 is a Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer that is actively recruiting participants, run by Jiping Wang, MD, PhD. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05701488, a Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer, is actively recruiting participants, sponsored by Jiping Wang, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- DEVICE SIRT
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05701488
The ClinicalTrials.gov registry entry for NCT05701488 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Jiping Wang, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT05701488 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT05701488 about?
NCT05701488 is a clinical study titled "SIRT With Tremelimumab and Durvalumab for Resectable HCC". The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventi...
What is the current status of trial NCT05701488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-04-21. Estimated completion is 2026-10-01.
What conditions does trial NCT05701488 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Resectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05701488?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), SIRT (DEVICE).
Who is sponsoring clinical trial NCT05701488?
This trial is sponsored by Jiping Wang, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05701488 being conducted?
This trial has 3 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.